VivoSeq
Other

Oocyte Maturation

0

Pipeline Programs

1

Active Trials

0

Companies Involved

Oocyte Maturation is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

8/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Completed6 · 50%
Unknown status4 · 33%
Not yet recruiting1 · 8%
Terminated1 · 8%

Trial Activity

12 trials

Intranasal Nafarelin For Triggering Oocyte Maturation
Not yet recruiting·FFundacion Dexeus·Phase 4·NCT06763926·134 enrolled
Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders
Completed··Phase 3·NCT04224818·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)